K. Shenk

发表

Novel inhibitors of fatty acid oxidation as potential metabolic modulators.

S. Kerwar, E. Elzein, K. Shenk, 2004, Bioorganic & medicinal chemistry letters.

Composes d'inhibition enzymatique

Barry A. Bunin, R. Borchardt, C. Crews, 2005 .

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

S. Demo, A. Chanan-Khan, D. Kuhn, 2005, Blood.

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

S. Demo, M. Aujay, T. Muchamuel, 2009, Journal of medicinal chemistry.

myeloma ubiquitin-proteasome pathway, against preclinical models of multiple Potent activity of carfilzomib, a novel, irreversible inhibitor of the

S. Demo, A. Chanan-Khan, Qing Chen, 2010 .

Novel inhibitors of fatty acid oxidation as potential metabolic modulators.

S. Kerwar, E. Elzein, K. Shenk, 2004, Bioorganic & medicinal chemistry letters.

CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability.

David A. Lustig, S. Kerwar, Xiaofen Li, 2004, Bioorganic & medicinal chemistry letters.

Methaqualone derivatives are potent noncompetitive AMPA receptor antagonists.

F. Menniti, K. Shenk, W. M. Welch, 2000, Bioorganic & medicinal chemistry letters.

New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.

David A. Lustig, S. Kerwar, K. Shenk, 2004, Bioorganic & medicinal chemistry letters.

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

T. Muchamuel, M. Bennett, F. Parlati, 2011, Clinical Cancer Research.

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.

James B Lorens, E. Suzuki, M. Aujay, 2009, Blood.

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

S. Demo, M. Aujay, M. Bennett, 2007, Cancer research.

Structure-affinity relationships of 5'-aromatic ethers and 5'-aromatic sulfides as partial A1 adenosine agonists, potential supraventricular anti-arrhythmic agents.

David A. Lustig, E. Elzein, K. Shenk, 2004, Bioorganic & medicinal chemistry letters.

Non-Proteasomal Targets of Proteasome Inhibitors Bortezomib and Carfilzomib

M. Bennett, F. Parlati, K. Shenk, 2008 .

Synthesis of conformationally restricted substance P antagonists

K. Shenk, S. Mclean, H. Howard, 1995 .